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ORIGINAL ARTICLE
In clinical trials, it is not uncommon to modify
trial and/or statistical procedures during the trial,
based on a review of interim data. The purpose is
not only to efficiently identify clinical benefits of
the test treatment under investigation, but also
to increase the probability of success of clinical
development. Trial procedures are referred to as the
eligibility criteria, study dose, treatment duration,
study endpoints, laboratory testing procedures,
diagnostic procedures, criteria for evaluability,
and assessment of clinical responses. Statistical
methods include randomization, study design,
study objectives/hypotheses, sample size, data
monitoring and interim analysis, statistical analy-
sis plan, and/or methods for data analysis. In this
article, we will refer to the adaptations (or modifi-
cations) made to the trial and/or statistical pro-
cedures as the adaptive design methods. Thus, an
adaptive design is defined as one that allows adap-
tations to trial and/or statistical procedures of the
trial after its initiation, without undermining the
validity and integrity of the trial.1 In their recent
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publication, which emphasized the feature of by
design adaptations only (rather than ad hoc adap-
tations), the Pharmaceutical Research Manufac-
turer Association Working Group on Adaptive
Design refers to an adaptive design as a clinical trial
design that uses accumulating data to decide on
how to modify aspects of the study as it continues,
without undermining the validity and integrity
of the trial.2 In many cases, an adaptive design is
also known as a flexible design.
The use of adaptive design methods for mod-
ifying the trial and/or statistical procedures of
ongoing clinical trials based on accrued data has
been practiced for several years in clinical research.
Adaptive design methods in clinical research are
very attractive to clinical scientists for the following
reasons. First, they reflect medical practice in the
real world. Second, they are ethical with respect
to both efficacy and safety (toxicity) of the test
treatment under investigation. Third, they are not
only flexible, but also efficient in the early phase
of clinical development. However, there can be
concern over whether the p value or confidence
interval regarding the treatment effect obtained
after the modification is reliable or correct. In ad-
dition, it is also of concern that the use of adap-
tive design methods in a clinical trial may lead to
a totally different trial, which is unable to ad-
dress scientific/medical questions that the trial is
intended to answer.3,4
Based on the adaptations employed, commonly
considered adaptive design methods in clinical
trials include, but are not limited to: (1) an adaptive
randomization design; (2) a group sequential de-
sign; (3) an N-adjustable design or a flexible sam-
ple size re-estimation design; (4) a drop-the-loser
(or pick-the-winner) design; (5) an adaptive dose-
finding design; (6) a biomarker-adaptive design;
(7) an adaptive treatment-switching design; (8) a
hypothesis-adaptive design; (9) an adaptive seam-
less trial design; and (10) a multiple adaptive de-
sign. Detailed information regarding these adaptive
designs can be found in Chow and Chang (2006).5
In this article, however, we will only focus 
on the two-stage adaptive seamless trial design,
which is probably the most commonly considered
adaptive design in clinical research and develop-
ment. A two-stage seamless adaptive trial design is
a study design that combines two separate studies
into one single study. In many cases, study objec-
tives and/or endpoints considered in a two-stage
seamless design may be similar but different (e.g.
a biomarker versus a regular clinical endpoint).
In this case, it is important to determine how the
data collected from both stages should be com-
bined for the final analysis. It is also of interest to
know how the sample size calculation/allocation
should be carried out to achieve the study objec-
tives originally set for the two stages (separate
studies). In this article, formulas for sample size
calculation/allocation are derived for cases in
which the study endpoints are continuous and
discrete (e.g. binary responses), and time-to-event
data that assume that there is a well-established
relationship between the study endpoints at dif-
ferent stages.
In the next section, the commonly employed
two-stage adaptive seamless design is briefly out-
lined. Also included in this section is a comparison
between the two-stage adaptive seamless design
and the traditional approach in terms of type I
error rate and power. The section titled Sample
Size Calculation/Allocation provides procedures
for sample size calculation/allocation for a two-
stage adaptive seamless design in which the study
endpoints at different stages are different. Some
practical issues when implementing a two-stage
adaptive seamless design are discussed in the sec-
tion titled Major Obstacles and Challenges. Some
concluding remarks are then given.
Two-stage Adaptive Seamless Design
Definition and characteristics
A seamless trial design is referred to as a program
that addresses study objectives within a single trial
that are normally achieved through separate tri-
als in clinical development. An adaptive seamless
design is a seamless trial design that uses data from
patients enrolled before and after the adaptation
in the final analysis.6 Thus, an adaptive seamless
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design is a two-stage design that consists of two
phases (stages), namely a learning (or exploratory)
phase and a confirmatory phase. The learning
phase provides opportunities for adaptations such
as stopping the trial early because of safety and/or
futility/efficacy based on accrued data at the end
of the learning phase. A two-stage adaptive seam-
less trial design reduces the lead time between
the learning (i.e. the first study for the traditional
approach) and confirmatory (i.e. the second study
for the traditional approach) phases. Most im-
portantly, data collected in the learning phase are
combined with those obtained in the confirmatory
phase for final analysis.
In practice, two-stage seamless adaptive trial
designs can be classified into the following four
categories depending on study objectives and
study endpoints at different stages: Category I—
same study objectives and same study endpoints;
Category II—same study objectives but different
study endpoints; Category III—different study
objectives but same study endpoints; Category
IV—different study objectives and different study
endpoints. Note that different study objectives are
usually referred to dose finding (selection) at the
first stage and efficacy confirmation at the second
stage, while different study endpoints are directed
to biomarkers versus clinical endpoints or the same
clinical endpoint with different treatment dura-
tions. Category I trial design is often viewed as a
similar design to a group sequential design with
one interim analysis, despite there being differences
between a group sequential and a two-stage seam-
less design. In this article, our emphasis is on
Category II designs. The results obtained can be
similarly applied to Category III and Category IV
designs, with some modification for controlling
the overall type I error rate at a prespecified level.
In practice, typical examples of a two-stage
adaptive seamless design include a two-stage adap-
tive seamless phase I/II design and a two-stage
adaptive seamless phase II/III design. For a two-
stage adaptive seamless phase I/II design, the ob-
jective of the first stage is biomarker development
and the study objective of the second stage is to
establish early efficacy. For a two-stage adaptive
seamless phase II/III design, the study objective
is for treatment selection (or dose finding) in the
first stage, while the study objective of the second
stage is efficacy confirmation.
Comparison
A two-stage adaptive seamless design is considered
a more efficient and flexible study design than
the traditional approach of having separate studies
in terms of controlling type I error rate and power.
For controlling the overall type I error rate, con-
sider, as an example, a two-stage adaptive seamless
phase II/III design. Let aII and aIII be the type I
error rate for phase II and phase III studies, re-
spectively. Overall, a for the traditional approach
of having two separate studies is given by a=aIIaIII.
In a two-stage adaptive seamless phase II/III de-
sign, on the other hand, the actual a is given by
a =aIII. Thus, a for a two-stage adaptive seamless
phase II/III design is actually 1/aII times larger than
the traditional approach for having two separate
phase II and phase III studies.
Similarly, for the evaluation of power, let PowerII
and PowerIII be the power for phase II and phase
III studies, respectively. Then, overall power for
the traditional approach of having two separate
studies is given by Power = PowerII × PowerIII. In the
two-stage adaptive seamless phase II/III design,
the actual power is given by Power = PowerIII. Thus,
the power for a two-stage adaptive seamless phase
II/III design is actually 1/PowerII times larger than
the traditional approach for having two separate
phase II and phase III studies.
In clinical development, it is estimated that it
will take about 6 months to 1 year before a phase
III study can be started after the completion of a
phase II study. This lead time is necessary for
data management, data analysis, and statistical/
clinical report. A two-stage adaptive seamless de-
sign could, with good planning, reduce lead time
between studies. The study protocol does not need
to be resubmitted to individual institutional review
boards for approval between studies if the two
studies have been combined into one single trial.
In addition, when compared with the tradi-
tional approach of having two separate studies, 
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a two-stage adaptive seamless trial design that com-
bines two separate studies may require a smaller
sample size to achieve the desired power to address
the study objectives of both individual studies.
Practical issues
As indicated earlier, a two-stage adaptive seamless
trial design combines two separate studies that may
use different study endpoints to address different
study objectives. As a result, we may have different
study endpoints and/or different study objectives
at different stages for a two-stage adaptive seamless
trial design. This leads to four different kinds of
two-stage seamless designs: (1) same study end-
point and same study objective; (2) same study
endpoint but different study objectives (e.g. dose
finding versus efficacy confirmation); (3) different
study endpoints (e.g. biomarker versus clinical end-
point) but same study objective; and (4) different
study endpoints and different study objectives.
One of the questions commonly asked when
applying a two-stage adaptive seamless design 
in clinical trials is how to perform sample size
calculation/allocation. For the first kind of two-
stage seamless design, the methods based on in-
dividual p values as described in Chow and Chang
can be applied.5 However, these methods are not
appropriate if different study endpoints are used
at different stages. Here, formulas and/or proce-
dures for sample size calculation/allocation, under
a two-stage seamless study design using different
study endpoints for achieving the same study
objective are derived for various data types in-
cluding continuous, discrete (binary response) and
time-to-event data, assuming that there is a well-
established relationship between the two study
endpoints. In other words, the study endpoint
considered in the first stage is predictive of that
employed in the second stage.
Sample Size Calculation/Allocation
Continuous study endpoints
Consider a two-stage seamless phase II/III study.
Let xi be the observation of one study endpoint
(e.g. a biomarker) from the ith subject in phase II,
i = 1, …, n, and let yj be the observation of another
study endpoint (the primary clinical endpoint)
from the jth subject in phase III, j = 1, …, m. Now,
assume that xi values are independently and identi-
cally distributed with E(xi) =n and Var(xi) = t2; and
assume that yj values are independently and iden-
tically distributed with E(yj) =m and Var(yj) =s2.
Chow et al have proposed using the established
functional relationship to obtain predicted values
of the clinical endpoint based on data collected
from the biomarker (or surrogate endpoint).7 Thus,
these predicted values can be combined with the
data collected in the confirmatory phase to develop
a valid statistical inference for the treatment effect
under study. Suppose that x and y can be related
in a straight-line relationship:
y = b0 + b1x + e (1)
where e is an error term with zero mean and vari-
ance z2. Furthermore, e is independent of x. In
practice, we assume that this relationship is well-
explored and that the parameters b0 and b1 are
known. Based on (1), the xi values observed in
the learning phase will be translated to b0 + b1xi
(denoted by ), and combined with the yi
values collected in the confirmatory phase.
Therefore, and yi values are combined for the
estimation of the treatment mean m. Consider
the following weighted-mean estimator:
(2)
where , and 0 ≤w≤1.
It should be noted that is the minimum vari-
ance unbiased estimator among all weighted-
mean estimators when the weight is given by:
(3)
if b1, t2 and s2 are known. In practice, t2 and 
s2 are usually unknown, and w is commonly 
estimated by:
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where and are the sample variances of 
and yj values, respectively. The corresponding es-
timator of m, which is denoted by:
(5)
is called the Graybill–Deal estimator of m. Based
on (5), we can test for differences between two
treatments, i.e. a test treatment versus a control
treatment. For illustration purposes, consider
testing the following hypotheses of equality:
H01 : m=m0 vs. H11 : m≠m0
Let m=rn. Then N= (1+r)n. It can be verified that
the following formula provides an approximation
to the required sample size n for achieving the
desired power at the 5% level of significance, and
is given as:
(6)
where is called the fixed 
sample size, and r =b12t2/s2. Note that in practice,
an initial estimate of r is often obtained by tak-
ing the ratio of the sample sizes obtained from
individual studies.
Binary responses
Lu et al considered cases in which the study 
endpoint is a discrete variable such as a binary
response.8 Suppose that the study duration of the
first stage is cL and the study duration of the sec-
ond stage is L with 0 < c < 1. Assume that the re-
sponse is determined by an underlying lifetime t,
and the corresponding lifetime distribution of t
for the test treatment is G1(t, θ1), while for the
control, it is G2(t, θ2). If there are n1 and m1 ran-
domly selected individuals in the first and second
stages for the test treatment, respectively, let r1 and
s1 be the numbers of respondents observed in the
first and second stages for the test treatment, re-
spectively. Similarly, for the control treatment,
there are n2 and m2 randomly selected individuals
for the control treatment. Let r2 and s2 be the
numbers of respondents observed in the first and
second stages, respectively. Based on these observed
data, the likelihood functions L(θi) for the test
treatment and the control treatment are:
for i = 1, 2; where i = 1 represents the test treatment
and i = 2 represents the control treatment. Assume
that the lifetimes under test and control treatments
are exponentially distributed with parameters 
l1 and l2, respectively. Thus, G1(t; θ1)=G(t, l1) and
G2(t; θ2) = G(t, l2). Then, the likelihood functions
become:
(7)
Let be the maximum likelihood estimate (MLE)
of li. Then, for i = 1, 2, can be found by solving
the following likelihood equation:
(8)
which is obtained by setting the first order partial
derivative L(li) with respect to li to zero. Note
that the MLE of li exists if and only if ri/ni and
si/mi do not equal 0 or 1 at the same time. Based on
the asymptotic normality of MLE (under suitable
regularity conditions), asymptotically follows
a normal distribution.9 In particular, as ni and mi
tend to infinity, the distribution of ( −li)/si(li)
converges to the standard normal distribution
where:
Let si( ) be the MLE of sili. Based on the 
consistency of MLE, by Slutsky’s theorem,10
( −li)/si( ) follows a standard normal distri-
bution asymptotically. Consequently, an approx-
imate (1 −a) confidence interval of li is given as
, where za/2 is the
(1 −a/2)-quartile of a standard normal distribu-
tion. Under an exponential model, comparison
of two treatments usually focuses on the hazard
rate li. For the comparison of two treatments 
in pharmaceutical applications, namely, control
( )/2 /2ˆ ˆ ˆ ˆ( ),  ( )i i i i i iz z− +a al s l l s l
ˆ
il
ˆ
il
ˆ
il
s l li i i
cL
i
LL n c e m ei i( ) ( ) ( )
/
= − + −− − λ −
−1 2 1 1 1 21 1( )
ˆ
il
ˆ
il
r c
e e
n r c m sicL
i
L i i i ii il l−
+
−
− − − − =
1 1
s
( ) ( ) ,0
ˆ
il
ˆ
il
e eL s m s Li i i i i( ) ( )l l− − − −1
L e ei
cL r n r cLi i i i i( ) ( ) ( )l l l= − − − −1
G L G Li
s
i i i
m
i ( , ) ( , )q q−1[ ] i is−
L G cL G cLi i
r
i i i
n r
i i i( ) ( , ) ( , )q q q= − −1[ ]
M
z z
fixed =
+
−
( )
( )
/a b s
m m
2
2 2
0
2
n
M
r r M
fixed
fixed
=
+
+ +
+
+−2
1 1
8 1
11( )
( )
( )r
r
r
⎛
⎝
⎜⎜⎜⎜⎜
⎞
⎠
⎟⎟⎟⎟⎟
ˆ ˆ ˆˆ (1 )GD y y= + −m w w
ˆiys2
2s1
2
versus treatment, it is often interesting to study
the hypotheses testing of equality, superiority,
noninferiority and equivalence of two treatments.
Furthermore, to facilitate the planning of a clinical
study, researchers are also interested in determining
the required sample size that would allow the
corresponding tests to achieve a given level of
power.11 For illustration purposes, consider testing
the following hypotheses for equality:
H0 : l1 = l2 vs. H0 : l1 ≠ l2 (9)
Let mi =rni and n2 = gn1, i=1, 2. Then the total sam-
ple size NT for two treatments is (1 + r)(1 + g)n1,
where:
(10)
and
Time-to-event data
Similar ideas can be applied to derive formulas for
sample size calculation/allocation for time-to-event
data.12 Let tijk denote the length of time from a
patient entering the trial to the occurrence of some
events of interest for the kth subject in the jth stage
of ith treatment, where k = 1, 2, …, nij, j = 1, 2, i = T
and R. Assume that the study durations for the
first and second stage are different, which are given
by cL and L respectively, where c < 1. Furthermore,
assume that tijk follows a distribution with G(t, qi)
and g(t, qi) as the cumulative distribution function
and probability density function with parameter
vector qi, respectively. The data collected from the
study can then be represented by (xijk, dijk), where
dijk = 1 indicates that the event of interest is ob-
served and that xijk = tijk, while dijk = 0 means that
the event is not observed during the study, i.e. xijk
is censored and that xijk < tijk. In clinical trials, it is
not uncommon to observe censored data due to
drop-out, loss to follow-up, or survival at the end of
the trials. In this article, for simplicity, we will only
consider the case where censoring is due to survival
at the end of the trials. Given the observed data,
the likelihood function for the test treatment and
the control treatment can be obtained as follows:
(11)
for i=T, R. In particular, suppose that the observed
time-to-event data are assumed to follow a Weibull
distribution. Denote the cumulative distribution
function (cdf) of a Weibull distribution with 
l, b > 0 by G(t; l, b) where .
Suppose that G(t; qT) = G(t; lT, bT) and G(t; qR) =
G(t; lR, bR), i.e. tijk follows the Weibull distribution
with cdf G(t; li, bi). Then the likelihood function
in (11) becomes:
(12)
where . Let l(li, bi) = log(L(li, bi))
be the log-likelihood function. Based on the log-
likelihood function, the MLEs of bi and li (denoted
by and ) can be obtained. Under the as-
sumption of asymptotic normality of MLE, it can
be shown that and are asymptotically nor-
mally distributed.9 Thus, formulas for sample size
calculation/allocation can be similarly obtained.
For illustration purposes, consider testing the fol-
lowing hypothesis of equality between medians:
H0 : MT = MR vs. H1 : MT ≠ MR (13)
where Mi is the median of G(t; li, bi), i = T, R. Let
be the MLE of Mi and ui be the variance of Mi.
We first consider the one treatment case, i.e. the
following hypothesis is considered:
H0 : MT = M0 vs. H1 : MT ≠ M0 (14)
Based on the asymptotic normality of MLE ,
we can then reject the null hypothesis at an ap-
proximate a level of significance if 
. Since approxi-
mately follows the standard normal distribution,
the power of the above test under H1 can be 
approximated by ,
where F is the distribution function of the standard
normal distribution. Hence, in order to achieve 
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a power of 1 – b, the required sample size satisfies
. If nT2 = rnT1, the
required total sample size N for the two phases is
given as N = (1 + r)nT1, where nT1 is given by:
(15)
Following the above hypothesis, the corresponding
sample size to achieve a prespecified power of 1 – b
with a significance level of a can be determined.
Hence, the corresponding required sample size for
testing the hypothesis in (13) satisfies the following
equation:
.
Let ni2 =rini1 and nR1 = gnT1. It can be easily derived
that the total sample size NT for the two treatment
groups in two stages is nT1[1 +rT + (1 +rR)g], with
nT1 given as:
(16)
Remarks
For illustration purposes, formulas for sample size
calculation/allocation were derived for continuous,
discrete, and time-to-event data for testing hypoth-
eses of equality, assuming that: (1) there is a well-
established relationship between different study
endpoints at different stages; and (2) the study
objectives for both stages are the same. Formulas
for sample size calculation/allocation for testing
superiority and noninferiority/equivalence can be
similarly derived.
In practice, it should be noted that such a 
relationship (i.e. one study endpoint is predictive
of the other study endpoint) may not exist. Thus,
the relationship should be validated based on
historical or observed data. When the study objec-
tives are different at different stages (e.g. dose
finding at the first stage and efficacy confirmation
at the second stage), the above derived formulas
are necessary for controlling the overall type I
error rate at a and for achieving the desired powers
at both stages.
Major Obstacles and Challenges
Instability of sample size
Under certain assumptions, sample size for testing
hypotheses of equality can be obtained as follows:
where s2/d2 is often estimated by sample mean
and sample variance from some pilot studies. Let
q =s2/d2. Then, it can be verified that bias of
is given by:
(17)
As a result, sample size obtained based on
can be substantial, and consequently
lead to instability of the sample size calculation.
To reduce bias, one may consider using the me-
dian of such that:
It can be verified that the bias of median estimate
is much less as compared with that of (17), i.e.
(18)
Equation (18) suggests that a bootstrap-median
approach be considered for a stable sample size
calculation in clinical trials.
Moving patient population
In practice, it is not uncommon to have protocol
amendments during the conduct of clinical tri-
als. As a result, it is likely that a shift in patient
population may have occurred before and after
protocol amendments. Chow et al13 suggested
assessing the shift in patient population using
the following sensitivity index:
(19)
where E0 and E are the effect sizes before and
after protocol amendment, and  = (1 + e/m0)/C
is the sensitivity index before and after protocol
E
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amendment. When a shift in patient population
has occurred, we recommend the following sam-
ple size adjustment:
(20)
where Nmin and Nmax are the minimum and maxi-
mum sample sizes, a is a constant, and sign(x)=1
for x>0; otherwise, sign(x)=−1. Note that a should
be chosen so that the sensitivity  is within an
acceptable range.
Concluding Remarks
In this article, formulas for sample size calcula-
tion/allocation under a two-stage seamless adaptive
trial design that combines two separate studies with
different study endpoints but the same study ob-
jective are derived assuming that there is a well-
established relationship between the two different
study endpoints. In practice, a two-stage seamless
adaptive trial design that combines a phase II
study for dose finding and a phase III study for
efficacy confirmation is commonly considered.14
In this case, the study objectives at different stages
are similar but different (i.e. dose finding versus
efficacy confirmation). A two-stage seamless adap-
tive trial means one that is able to address both
study objectives with the desired power, and com-
bine data collected from both stages for a final
analysis. In this case, it is important to establish
how to control the overall type I error rate and
achieve the desired powers at both stages. A typical
approach is to consider precision analysis at the
first stage for dose selection and power the study
for detecting a clinically meaningful difference at
the second stage (by including the data collected at
the first stage for the final analysis). For precision
analysis, the dose with highest confidence level for
achieving statistical significance will be selected
under some prespecified selection criteria. Some
adaptations such as dropping the inferior arms
or picking up the best dose, stopping the trial
early because of safety and/or futility/efficacy, or
adaptive randomization may be applied at the
end of the first stage. Although this approach
sounds reasonable, it is not clear how the overall
type I error rate can be controlled. More research
is needed.
From a clinical point of view, adaptive design
methods reflect real clinical practice in clinical
development. Adaptive design methods are very
attractive because of their flexibility, and are es-
pecially useful in early clinical development. How-
ever, many researchers are not convinced and still
challenge its validity and integrity.15 From the sta-
tistical point of view, the use of adaptive methods
in clinical trials makes good statistical practice
even more complicated. The validity of the use of
adaptive design methods is not well established.
The impact of statistical inference on treatment
effect should be carefully evaluated within the
framework of moving target patient population
as the result of protocol amendments (i.e. modi-
fications made to the study protocols during the
conduct of the trials). In practice, regulatory agen-
cies may not realize that the adaptive design
methods for review and approval of regulatory
submissions have been employed for several years
without any scientific basis. Guidelines regarding
the use of adaptive design methods must be de-
veloped so that appropriate statistical methods
and statistical software packages can be developed
accordingly.
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